EUVIMEDEUVIMED entdecken
Kommentar

Comment on ‘Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study’

Chandler Johnson iD, Payton Smith, Kathryn Haran, Allison Kranyak, Wilson Liao, Tina Bhutani

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljad529 ↗

Kurz gefasst

Kommentar in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Chandler Johnson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of California San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this letter to the editor, we respond to the article by Merola et al. titled ‘Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study’. We add to the authors’ discussion on the discrepancy between objective and subjective measures of sleep in people with atopic dermatitis treated with dupilumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDouble-Blind MethodSleepClinical Trials, Phase IV as TopicRandomized Controlled Trials as Topic

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.

ORCID-Profile: Chandler Johnson

Zitieren

APA

Johnson, C., Smith, P., Haran, K., Kranyak, A., Liao, W., & Bhutani, T. (2024). Comment on ‘Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study’. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad529

Vancouver

Johnson C, Smith P, Haran K, Kranyak A, Liao W, Bhutani T. Comment on ‘Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study’. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad529

BibTeX
@article{Johnson2024,
  author = {Johnson, Chandler and Smith, Payton and Haran, Kathryn and Kranyak, Allison and Liao, Wilson and Bhutani, Tina},
  title = {Comment on ‘Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study’},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljad529}
}
Kostenlos starten →